Multiple sclerosis drug trials: Luciano Rossetti on the recent cladribine approval

Written by Lauren Pulling, Editor

This month saw the European Commission approve cladribine 10 mg tablets (MAVENCLAD®) for the treatment of highly active relapsing multiple sclerosis (MS). In this interview, we speak to Luciano Rossetti, Global Head of R&D at Merck, who discusses the recent approval, as well as the current MS drug pipeline. What are the current unmet needs for patients with MS? MS is associated with a substantial clinical and economic burden on patients, caregivers and healthcare systems, and is more pronounced in patients with high disease activity. Although many treatments for MS already exist, they generally involve continuous suppression of the immune...

To view this content, please register now for access

It's completely free